Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 27;24(13):10713.
doi: 10.3390/ijms241310713.

Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers

Sonia Algarate  1   2   3 , Laura Serrano  1   3 , Jessica Bueno  1   2 , Beatriz Herrero-Cortina  1   3   4 , Elena Alvarado  1 , María T González-Barriga  1   3 , María Ducons  1 , Jesica Montero-Marco  1   3 , Sara Arnal  1 , Beatriz Acha  1   3 , María Riesgo  1 , Ana Taboada  1   3 , Pilar Sanz-Burillo  1   3 , Cristina Yuste  1   3 , Rafael Benito  1   2   3 , On Behalf Of The Ripovac Study Group
Affiliations

Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers

Sonia Algarate et al. Int J Mol Sci. .

Abstract

Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines.

Keywords: SARS-CoV-2; booster vaccine; post-vaccine IgG antibody persistence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schedule of RIPOVAC study. Data from RIPOVAC 1 in [2]. Third sample refers to samples analyzed in this study.
Figure 2
Figure 2
Antibody level variation eight months after third dose of vaccine in uninfected patients. Green lines indicate cases with elevation. Red lines indicate cases with a decrease.
Figure 3
Figure 3
Antibody levels after COVID vaccine at 2, 8 (taken from [2]), and 18 months after vaccination.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Krammer F. SARS-CoV-2 vaccine in development. Nature. 2020;586:516–527. doi: 10.1038/s41586-020-2798-3. - DOI - PubMed
    1. Serrano L., Algarate S., Herrero-Cortina B., Bueno J., González-Barriga M.T., Ducons M., Montero-Marco J., Acha B., Taboada A., Sanz-Burillo P., et al. Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection. J. Appl. Microbiol. 2022;133:1969–1974. doi: 10.1111/jam.15699. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;31:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Núñez López C., González de Abreu J.M., Pérez-Blanco V., de Miguel Buckley R., Romero Gómez M.P., Díaz-Menéndez M. La Paz Health Care Workers Vaccination Study Group; Appendix. La Paz Health Care Workers Vaccination Study Group. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Enferm. Infecc. Microbiol. Clin. 2023;41:33–35. doi: 10.1016/j.eimc.2021.06.021. - DOI - PMC - PubMed